BMS Opts In On Exscientia’s AI-Designed Immune-Modulating Candidate

Bristol Myers Squibb Will Handle Compound’s Clinical, Commercial Development

 
• By Sten Stovall
  
AI-designed drug is first in duo's multi-target collaboration to reach in-license milestone • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip